2
Introduction
Non-Hodgkin lymphoma (NHL) is a collective term for a heterogeneous group of lymphoproliferative malignancies with subtypes ranging from slow-growing to aggressive with different responses to available treatment. In 2015, there were 71,850 estimated new cases of NHL and 19,790 resulting deaths 1 . Current treatment modalities for B-cell NHL (B-NHL) may be effective in first line therapy, but many patients relapse or are refractory, necessitating the development of improved therapies 2, 3 .
We identified apilimod from our clinical stage compound library as a potent targeted agent with robust cytotoxic activity on B-NHL. Apilimod was previously identified as an inhibitor of toll-like receptor (TLR)-induced IL-12 and IL-23 cytokine production, and was evaluated in clinical trials as an immunomodulatory agent for treatment of Th1-and Th17-mediated inflammatory diseases 4, 5 . These trials included normal healthy volunteers (Phase 1) as well as psoriasis, rheumatoid arthritis, and
Crohn's disease patients (Phase 2) 4, 6, 7 . Altogether, greater than 700 subjects were treated and apilimod was well-tolerated with mild to moderate side effects including headache, fatigue, dizziness and nausea. However, apilimod did not meet the primary endpoints in Phase 2 inflammatory disease indications and further clinical development was abandoned 4, 6 .
While these clinical trials were performed prior to identification of the direct target, inhibition of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) has since been shown to underlie the selective inhibition of immune cell production of IL-12/IL-23 8 .
PIKfyve is an endosomal lipid kinase targeted to the cytoplasmic leaflet of endosomes via protein-lipid interactions between its FYVE domain and phosphatidylinositol-3-phosphate within the endosomal membrane 9 . At endosomes, PIKfyve phosphorylates PI3P to generate PI(3,5)P 2 , which in turn serves to control endolysosomal membrane traffic [10] [11] [12] [13] [14] .
A role for PIKfyve inhibition for anti-cancer therapy has only been minimally explored. Anti-proliferative activity of apilimod to date has been limited to experiments on non-small cell lung cancer lines 15 and under nutrient starvation 16 . A role for PIKfyve in controlling tumor cell invasiveness has also been described 17, 18 . Here, we validate PIKfyve kinase as a target for B-NHL and show that inhibition by apilimod has powerful and selective anti-proliferative and cytotoxic effects. Furthermore, through a genomewide CRISPR screen we identified lysosome-related genes that determine the remarkable sensitivity of B-NHL cells to apilimod. These findings, along with observations that apilimod treatment robustly impairs endolysosomal membrane traffic, point to disruption of lysosomal homeostasis as an important component of the cytotoxic effects of apilimod.
Collectively, these findings provide a promising new approach for treating multiple subtypes of B-NHL as a single agent, or in combination with existing therapies.
Methods

Cell-Titer Glo TM Assays
Cells were seeded into 96-well plates at a density within log growth phase and treated with indicated drugs for 5 days. Plates were developed with Cell-Titer Glo TM assay (Promega) according to the manufacturer's instructions. The IC 50 for each cell line was determined using Graphpad Prism 6 TM software. Data were log transformed and subjected to non-linear regression (curve fit) using the sigmoidal dose-response (variable slope) equation, constraining the bottom at 0 and the top at 100. Experiments were performed in duplicate and repeated a minimum of two independent times to obtain the average IC 50 values. For Caspase 3/7 activity, the same procedure was performed with the Caspase Glo TM assay (Promega).
Knockdown Experiments
shRNA-mediated knockdown was performed by cloning annealed hairpin oligos into
Tet-pLKO-puro (Addgene plasmid 21915) for doxycycline inducible repression of PIKFYVE (see Supplement). Constructs were transfected into 293T cells with pVSVG and Delta 8.9 packaging plasmids and lentivirus-containing supernatant was harvested 72
hours post transfection. B-NHL cell lines were transduced by spinoculation with 50%
virus supernatant with 8 ug/ml polybrene for 1.5 hours at 800 x g and drug-selected with 2 ug/ml puromycin. Surviving Tet-pLKO-puro pools were expanded and treated with 1-2 ug/mL doxycycline to induce hairpin expression.
Cell Line Transfections and Overexpression
Human PIKFYVE, CTSD and TFEB cDNAs were amplified using Kapa HiFi (Kapa Biosystems) and cloned into the piggyBac transposon construct PJ[puro] 19 Mlu I site using NEBuilder HiFi Assembly Mix (New England Biolabs). Five million cells were electroporated with a 2:1 ratio of PJ[puro] and ACT-PBase with the Neon transfection system (ThermoFisher Scientific). Pools were selected for one week with 2 ug/mL puromycin.
Xenograft Experiments
All animal studies were conducted under approved animal care protocols and AAALAC standards. Cells were propagated as described in the supplement for each specific model.
Six to eight week old female mice were γ -irradiated 24 hours before tumor cell inoculation and were dosed as described in the supplement. Mice that had an adverse event before drug treatment completion were removed from the data set. See Supplement for specific details.
FACS Analysis
Cells were labelled with 7-AAD (BD Biosciences), Annexin V (BD Biosciences) or
LysoTracker Deep Red (ThermoFisher Scientific) according to the manufacturers' recommendations and analyzed on a BD LSRII (BD Biosciences).
Global Gene Expression Analysis
SU-DHL-10 and WSU-DLCL2 cell lines were treated with apilimod (300 nM) or vehicle for 24 hours. RNA was isolated from three biological replicates using the RNeasy Kit (Qiagen). 100 ng of RNA was amplified using the Ion AmpliSeq Transcriptome Human Gene Expression kit (Ion AmpliSeq Transcriptome Human Gene Expression Kit, ThermoFisher) prior to Proton sequencing (Proton, ThermoFisher). Reads were demultiplexed and aligned to the reference library using the AmpliSeq RNA plug-in on the Ion Torrent Server. The differential expression between treated and control samples was determined using the DESeq2 library 20 from R Bioconductor software 21 (http://www.bioconductor.org). Statistical significance was established by calculation of the false discovery rate (FDR) and genes with FDR < 0.05 were considered differentially regulated.
Gene Ontology Analysis
Gene ontology analysis was performed on the commonly up-regulated and downregulated genes, using the Enrichr platform 22 , and 'GO Cellular Component' term.
CRISPR screen
The dual vector lentiviral GeCKO V2 human library 23 was used to perform a genetic screen to identify genes that are required for apilimod sensitivity in the SU-DHL-10 DLBCL cell line. Four independent pools were screened at three concentrations of apilimod: 0 nM, 300 nM, and 600 nM. See Supplement for full details. unapproved drugs that span a wide range of diseases. To systematically probe our library for drugs with anti-proliferative activity, we developed a high-throughput screening assay using a Tsc2 null murine embryonic fibroblast (MEF) cell line displaying constitutively elevated mTORC1 signaling 24 . Apilimod was identified among the most potent drugs screened and was subsequently shown to have an IC 50 of 20 nM (Figures S1A and S1B).
Results
High
B-NHL cells display acute sensitivity to apilimod in vitro
Given the potency of apilimod in our initial screen, we next profiled its anti- To perform a comprehensive analysis of selectivity, we profiled apilimod at 1 uM against a panel of 456 normal and disease-related protein and lipid kinases 27 . The results from this screen showed that apilimod only bound to PIKfyve and not to any other kinase in the panel, including other structurally related lipid kinases such as Type I and Type II PIP5K ( Figure S4C ). These data confirmed and extended previous analyses showing that apilimod had selectivity for PIKfyve when profiled against 41, or 276 kinases 8, 28 .
We next confirmed that suppression of PIKFYVE levels via inducible expression of shRNAs is sufficient to inhibit the proliferation of B-NHL in vitro ( Figure 1D and Figure S5 ). Furthermore, we identified through in vitro selection (21 days, 500 nM apilimod), a missense mutation in PIKFYVE that conferred apilimod resistance in the WSU-DLCL2 cell line. This N1939K mutation is predicted to reside in the ATP-binding pocket of the PIKfyve kinase domain 28 . Stable expression of the N1939K mutant conferred greater than 150-fold drug resistance as compared to the parental WSU-DLCL2 line ( Figure 1E ), confirming that PIKfyve is the critical target responsible for antiproliferative activity of apilimod in B-NHL.
Apilimod displays anti-tumor activity in B-NHL in vivo
We next tested the effects of apilimod in in vivo models of lymphoma. The in vivo 
Apilimod-induced cell death in B-NHL correlates with autophagy dysfunction
To determine whether apilimod induced cytotoxicity in cancer cells, we costained B-NHL with Annexin V, a marker for early apoptosis, and 7-AAD, a membrane impermeant marker of nonviable cells. We observed a marked loss of membrane integrity and increased Annexin V staining in apilimod-treated B-NHL, confirming induction of cell death ( Figure 3A and Figure S6A ). Although Annexin V staining could be indicative of early apoptosis, the precise mechanism of apilimod-induced cell death appears to be non-canonical. We do not observe marked increases in DEVD-UltraGlo™ Luciferase cleavage (surrogate for caspase 3/7 activity) in apilimod-treated B-NHL at physiologically relevant concentrations ( Figure 3B and Figure S6B ), nor do we observe a significant rescue of cell viability with caspase, cathepsin or necroptosis inhibitors across the cell lines tested ( Figures 3C-3E and Figure S6C -E). Interestingly, apilimod appears to disrupt the completion of autophagy as indicated by an increase in the levels of p62 and LC3-II ( Figure 3F and Figure S6F ). Moreover, since co-treatment with bafilomycin does not further elevate LC3-II levels, but rapamycin does ( Figure 3F and Figure S6F ), apilimod most likely impairs the lysosomal degradation of autophagosomal cargo.
Together this data suggests that apilimod blocks autophagy and its effects are distinct from apoptosis, lysosomal membrane permeabilization, and necroptosis.
Transcription Factor EB (TFEB) confers sensitivity to apilimod in B-NHL
To further elucidate apilimod's mechanism of action, we investigated global gene expression changes after treatment of B-NHL tumor lines ( Figure 4A ). Gene ontology analysis revealed a significant up-regulation of lysosomal and autophagy-related genes, results that were further confirmed with Gene Set Enrichment Analysis over a comprehensive autophagy-lysosomal signature ( Figure 4B and Figure S7 ). Consistent with these changes in gene expression, we observed an expansion of the acidified compartment following acute apilimod treatment of B-NHL cells ( Figure 4C ). This result suggested that lysosome biogenesis was up-regulated by apilimod. Since TFEB is a master transcriptional regulator of lysosomal gene expression and undergoes nuclear translocation following dephosphorylation [29] [30] [31] , we explored TFEB phosphorylation status and sub-cellular localization upon apilimod treatment. We observed that within two hours of apilimod treatment, TFEB is dephosphorylated (revealed by an increase in electrophoretic mobility) and translocated into the nucleus ( Figure 4D ), as has been observed in other cell types with apilimod 32 and Pikfyve deletion 33 .
We next tested the potential role of TFEB for conferring sensitivity to apilimod in B-NHL. TFEB was over-expressed in the TFEB-deficient B-NHL cell line CA46 and we observed that apilimod sensitivity was enhanced by greater than 50-fold ( Figure 4E and 5B). This TFEB-mediated sensitivity also correlated with an increase in the apilimodinduced expansion of the acidified compartment, consistent with a role for lysosome dysfunction in driving apilimod-induced cell death ( Figure S8 ). To determine whether there was a correlation between TFEB expression and apilimod sensitivity, we analyzed the expression levels of TFEB across different cancer types from the Cancer Cell Line Encyclopedia (CCLE) database 34 . Strikingly, TFEB was expressed most highly in B-NHL compared to other tumor types ( Figure 4F ). These observations support the hypothesis that elevated TFEB expression levels are an important contributor to the selective sensitivity of B-NHL cell lines to apilimod.
Disruption of lysosomal homeostasis is central to apilimod's mechanism of action
Previous studies in cell types other than B-NHL have shown that the PI(3,5)P 2 depletion following PIKfyve inhibition or deletion results in a striking swelling of endolysosomal organelles 8, 11, 35, 36 . We also noted this endolysosomal swelling phenotype (vacuolization) in apilimod-treated B-NHL cells ( Figure 5A ). This change in the shape and size of endosomes and lysosomes suggests a major imbalance in the membrane traffic into and out of these organelles. Lysosome function is critically dependent on the vesicular delivery and maturation of numerous enzymes that collaborate within lysosomes to degrade macromolecules. Consistent with an intracellular trafficking defect, we observed a dose-dependent increase in the pro-(inactive forms) forms of cathepsins A and D that is further enhanced by elevated TFEB expression (Fig. 5B) . To confirm that apilimod was indeed causing accumulation of pro-cathepsin and not simply raising cathepsin expression, we overexpressed cathepsin D and once again observed a selective increase of pro-cathepsin D levels upon apilimod treatment ( Figure S9) . These results collectively demonstrate that apilimod treatment impairs the maturation of key lysosomal proteases.
Genome wide CRISPR screen identifies lysosomal proteins as key determinants of apilimod-mediated sensitivity
We next used CRISPR technology to perform a genome-wide loss of function genetic screen in the SU-DHL-10 B-NHL cell line to identify genes that are necessary for apilimod sensitivity (detailed in Figure S10 ). For this purpose, we used the GeCKO library that has been successfully implemented in previous CRISPR-based resistance screens 23, 37 . Briefly, cells were infected in parallel with the GeCKO A and B libraries and expanded in the presence of 300 nM or 600 nM apilimod. After 3 days of treatment, surviving cells were further expanded and reselected in the presence of apilimod for another 3 days. Genomic DNA from these pools was subsequently analyzed for the identification of enriched single-guide RNAs (sgRNAs).
Remarkably, the endosomal/lysosomal associated genes OSTM1, CLCN7, SNX10, as well as TFEB were top hits arising from this analysis ( Figure 5C ). This identification of TFEB (in addition to data from Figure 4E ) further establishes this transcription factor as an important determinant of apilimod sensitivity. Interestingly, CLCN7 is a TFEB target gene 38 and together with OSTM1 encodes a Cl-/H+ exchanger 39 that is important for lysosome acidification 40, 41 . Furthermore, sorting nexin 10 (SNX10) has previously been shown to play an important role in the control of endolysosomal membrane traffic and induces large lysosomal vacuoles when over-expressed 42 . To validate these molecular candidates, we performed targeted CRISPR-mediated deletion of OSTM1 and CLCN7 in B-NHL cells, and observed that loss of each gene indeed conferred >100-fold apilimod resistance ( Figure 5D ).
In order to elucidate the connection between TFEB and the CLCN7/OSTM1 transporter, we examined the effect of knocking out each of these components on apilimod-induced lysosomal expansion. Interestingly, loss of either chloride transporter component (CLCN7 or OSTM1), but not TFEB, blocked both apilimod-induced expansion of the acidified compartment and vacuolization ( Figure 6 ). Importantly, apilimod sensitivity correlated with these endolysosomal phenotypes as CLCN7 and OSTM1 CRISPR knockout confer complete resistance and TFEB CRISPR knockout only provides partial resistance ( Figure 5D and Figure S11 ). This points to TFEB activity functioning upstream or parallel to the CLCN7/OSTM1 transporter, which appears to be directly required for apilimod-induced endolysosomal disruption. Together, these results support a model where CLCN7/OSTM1 is central to the susceptibility of B-NHL to apilimod-induced killing.
Discussion
In this study we identified apilimod as a drug with potent and selective anticancer activity against B-NHL. To better understand how apilimod exerts its cytotoxic effect, we first sought to unambiguously identify its relevant molecular target in B-NHL cells and found it to be the phosphosinositide kinase PIKfyve, matching what was previously observed in immune cells 8 . By profiling apilimod against a human kinome library, we found a remarkable selectivity for PIKfyve over all other kinases examined.
Validation that PIKfyve inhibition was directly responsible for apilimod activity was . We searched for a connection between expression of IL-23 receptor in sensitive versus resistant lines, but did not observe any significant correlation (data not shown). Interestingly, inhibition of PIKfyve has also been shown to inhibit cancer cell invasion 17, 18 and growth under nutrient deprivation 16 , which may lead to enhanced antitumor activity against metastatic and nutrient-deprived tumors in vivo.
The precise mechanism through which apilimod exerts its selective killing activity on specific cancer cells is of great interest. Consistent with expectations arising from the established role for PIKfyve as an important regulator of endosome and lysosome function [10] [11] [12] [13] 35, 36, 43 , our experiments have provided multiple pieces of evidence that point to apilimod's disruption of late endosome/lysosome function as being a major factor driving apilimod-induced cancer cell cytotoxicity.
First, we and others have observed that loss of PIKfyve activity results in disruption of endososome and lysosome membrane trafficking [10] [11] [12] [13] 35, 36, 43 , as revealed by the robust formation of swollen cytoplasmic vacuoles following apilimod treatment. This massive apilimod-induced trafficking defect likely disrupts multiple aspects of lysosome function. Indeed, we observed that apilimod treatment in B-NHL impairs the degradation of autophagic cargo and blocks cathepsin maturation ( Figures 3F and 5B) as has been reported for other PIKfyve inhibitors [43] [44] [45] and genetic deletion 36 . Furthermore, cathepsin inhibition does not block apilimod activity ( Figure 3D ), suggesting a mechanism distinct from classical lysosomal membrane permeabilization 46 .
Second, we observe that apilimod increases the nuclear abundance of TFEB and induces the up-regulation of numerous lysosome and autophagy-related genes as observed for TFEB activation in other cell types 38, 47, 48 . Interestingly, as previously reported 32 , apilimod-induced TFEB nuclear translocation is independent of mTOR inhibition ( Figure S3B ). We were also unable to detect a role for calcineurin which was recently shown to regulate TFEB dephosphorylation and nuclear translocation, 
